Cipher Pharmaceuticals Inc

Type: Company
Name: Cipher Pharmaceuticals Inc
First reported 22 hours ago - Updated 22 hours ago - 1 reports

Today In SA PRO: Thursday, July 31

Top Idea: Tree.com by Alpha Gen Capital: Long / Internet Marketing / GARP / Small-Cap / Market Share Growth / Underfollowed / 35% UpsideOutstanding Performance Award Winner #1: Long idea on IDIX (Idenix Pharmaceuticals) by Unconventional Capital Wisdom, ... [Published Seeking Alpha - 22 hours ago]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Cipher's Business Continues To Hum Along

By Jason Napodano :(Editor's Note: This stock also trades on the Toronto Stock Exchange under symbol DND, with average daily volume of C$200,000.)Related Biotechnology, Pharmaceutical and Healthcare NewsOn July 30, 2014, Cipher Pharmaceuticals ( OTC:CPHMF ... [Published BioPortfolio - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Ranbaxy signs licensing agreement with Cipher for anti-acne therapy in Brazil

Ranbaxy Laboratories Limited, a pharmaceuticals company, has signed a licensing agreement with Cipher Pharmaceuticals Inc. to exclusively market, sell and distribute Cipher's isotretinoin capsules in Brazil. The agreement extends the current relationship ... [Published Individual.com - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 31 2014 - 1 reports

AT&T’s “Outperform” Rating Reaffirmed at Zacks (T)

AT&T (NYSE:T)Zacks’ analyst wrote, "On July 30, 2014, Cipher Pharmaceuticals reported financial results for the second quarter ended June 30, 2014. Total revenues in the quarter were $8.7 million, up 58% over the second quarter 2013 and $1.2 million above ... [Published American Banking News - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 2 reports

Cipher reports financial results for Q2 2014

Toronto Stock Exchange Symbol: DND "Our second quarter results show strong increases in revenue, earnings and cash, as our product portfolio continues to perform very well overall," said Shawn O'Brien Total revenue for Q2 2014 was $8.7 million Re and ... [Published Noodls - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

RANBAXY, CIPHER INK PACT

that it has signed a licensing pact with Cipher Pharmaceuticals of Canada to exclusively market its isotretinoin capsules in Brazil . With this, Ranbaxy has extended its current relationship with Cipher. ... [Published 4 Traders - Jul 30 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 11 reports

Pharma shares in demand; Healthcare index hits new high

Shares of frontline pharmaceutical companies are in demand on the bourses with the BSE Healthcare index hitting new high in an otherwise weak market today.S&P Healthcare index, gauge of pharmaceutical companies, has surged 1% or 130 points compared to ... [Published Business Standard India - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Sensex down more than 100 points; Capital goods, metal stocks decline

The market, which retreated after a slightly positive start, has slipped a bit deeper into the red in late morning trade, with key stocks from information technology, capital goods, power, realty and metal sectors losing significant ground due to sustained ... [Published Sify - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Ipca halts drug exports to US

Mumbai, July 24: Ipca Laboratories today said it was voluntarily suspending shipments of drug ingredients from one of its plants in the country, following concerns expressed by the US Food and Drug Administration (FDA). The mid-sized company said the ... [Published Calcutta Telegraph - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Stocks in play: Pediapharm Inc.

09:50 AM EST - Cipher Pharmaceuticals Inc. : announced it has entered into a definitive distribution and supply agreement with Ranbaxy Laboratories Ltd. under which Cipher has granted Ranbaxy the exclusive right to market, sell and distribute Cipher's ... [Published BayStreet.ca - Jul 24 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Cipher to host Q2 results call July 30

Mr. Norm Evans reportsNOTICE OF CIPHER PHARMACEUTICALS INC. Q2 2014 CONFERENCE CALLCipher Pharmaceuticals Inc. will host a conference call for its second quarter 2014 financial results onWednesday, July 30, 2014.Second quarter 2014 conference callWhen: ... [Published Stockwatch - Jul 16 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Novadaq and Cipher make biotech buy list

Extended CoverageThey may be high risk, but they also offer the potential for high rewards. BNN’s Pamela Ritchie talks top biotech stock picks with Douglas Loe, Healthcare and Biotechnology analyst at Euro Pacific Canada. Loe’s buy recommendations include ... [Published Business News Network - Jul 07 2014]

Quotes

Commenting on the partnership, Sanjeev I Dani, Executive vice president & Head, Global Strategy, Ranbaxy said, "We are pleased to take this novel formulation of isotretinoin to the additional large market of Brazil. I am sure it would prove to be a valuable option for dermatologists and patients who suffer from severe recalcitrant nodular acne. We will utilise our strong front-end capabilities in making this product available in Brazil."
Zacks’ analyst wrote, "On July 30, 2014, Cipher Pharmaceuticals reported financial results for the second quarter ended June 30, 2014. Total revenues in the quarter were $8.7 million, up 58% over the second quarter 2013 and 1.2 million above of our estimate for revenues of $7.5 million. Revenues were driven by growing royalties of Absorica from U S commercial partner Ranbaxy and strong revenues on Lipofen thanks to wholesaler inventory stocking. Cipher also recorded $0.50 million in product sales relating to sales of Epuris in Canada. This was generally in-line with expectations. We continue to believe the Cipher story is attractive and recommend purchase up to $12 per share. "
Toronto Stock Exchange Symbol: DND "Our second quarter results show strong increases in revenue, earnings and cash, as our product portfolio continues to perform very well overall" said Shawn O'Brien TotalTotal revenue for Q2 2014 was $8.7 million Re and Development expense for Q2 2014 was $0.3 million
Akhil Gupta, Chairman, Bharti Infratel said, "One of the key focus areas for the industry as well as the Government is internet connectivity across India. Industry expects clear road map for spectrum auctions in all bands, spectrum sharing and trading. All these steps shall accelerate the growth of data networks, users and usage which should result in growing demand for towers and higher sharing by operators. Bharti Infratel with its superior network footprint and service quality standards has the potential to be a major beneficiary of this growth." The company's board of directors declared an interim dividend of Rs 4.50 per share

More Content

All (37) | News (36) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Today In SA PRO: Thursday, July 31 [Published Seeking Alpha - 22 hours ago]
Cipher's Business Continues To Hum Along [Published BioPortfolio - Jul 31 2014]
Cipher's Business Continues To Hum Along [Published Seeking Alpha - Jul 31 2014]
Ranbaxy signs licensing agreement with Cipher f... [Published Individual.com - Jul 31 2014]
Cipher Pharmaceuticals (DND) Releases Quarterly... [Published American Banking News - Jul 31 2014]
AT&T’s “Outperform” Rating Reaffirmed at Zacks (T) [Published American Banking News - Jul 30 2014]
Canadian earnings declared Wednesday: CGI, Tors... [Published Brandon Sun - Jul 30 2014]
Cipher reports financial results for Q2 2014 [Published Noodls - Jul 30 2014]
Cipher reports financial results for Q2 2014 [Published Canada NewsWire - Jul 30 2014]
RANBAXY, CIPHER INK PACT [Published 4 Traders - Jul 30 2014]
Indian stock market daily morning report (July ... [Published Stock Markets Review - Jul 28 2014]
Indian stock market and companies daily report ... [Published Stock Markets Review - Jul 28 2014]
Pharma shares in demand; Healthcare index hits ... [Published Business Standard India - Jul 25 2014]
Sensex down more than 100 points; Capital goods... [Published Sify - Jul 25 2014]
Ranbaxy gains after inking licensing pact with ... [Published India Infoline - Jul 25 2014]
Wipro drops after Q1 results [Published Business Standard India - Jul 25 2014]
Ranbaxy hits 52-week high after inks pact with ... [Published Business Standard India - Jul 25 2014]
Ranbaxy Laboratories gains on inking licensing ... [Published Arihant Capital - Jul 25 2014]
Ipca halts drug exports to US [Published Calcutta Telegraph - Jul 25 2014]
Wipro in focus after Q1 results [Published Business Standard India - Jul 25 2014]
Market may open flat to marginally lower [Published Business Standard India - Jul 25 2014]
Ranbaxy, Cipher Agree To Expand Acne Drug Licen... [Published Health News Daily - Jul 25 2014]
Ranbaxy, Cipher Agree To Expand Acne Drug Licen... [Published BioPortfolio - Jul 25 2014]
Ranbaxy Laboratories : and Cipher Announce Sign... [Published 4 Traders - Jul 24 2014]
Ranbaxy inks licensing pact with Canada's Ciphe... [Published Business Standard India - Jul 24 2014]
Ranbaxy, Cipher join hands for Brazil venture [Published Hindu Business Line - Jul 24 2014]
Stocks in play: Pediapharm Inc. [Published BayStreet.ca - Jul 24 2014]
Ranbaxy inks pact with Cipher to sell acne drug... [Published Financial Express - Jul 24 2014]
Ranbaxy to market Cipher Pharma's isotretinoin ... [Published PharmaBiz - Jul 24 2014]
Cipher Pharmaceuticals and Ranbaxy Announce Dis... [Published TickerTech.com - Jul 24 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Cipher, Andrómaco ink supply agreement for isot... [Published PBR - News - Jun 19 2014]
Canada-based Cipher Pharmaceuticals has entered into a definitive distribution and supply agreement with Laboratorios Andrómaco (Andrómaco) for isotretinoin product in Chile. ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.